INHIBITION OF ACYL-COA - CHOLESTEROL ACYLTRANSFERASE ACTIVITY BY CYCLODEPSIPEPTIDE ANTIBIOTICS

被引:159
|
作者
TOMODA, H
HUANG, XH
CAO, J
NISHIDA, H
NAGAO, R
OKUDA, S
TANAKA, H
OMURA, S
ARAI, H
INOUE, K
机构
[1] KITASATO INST, BIOL FUNCT RES CTR, MINATO KU, TOKYO 108, JAPAN
[2] KITASATO UNIV, SCH PHARMACEUT SCI, MINATO KU, TOKYO 108, JAPAN
[3] UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN
来源
JOURNAL OF ANTIBIOTICS | 1992年 / 45卷 / 10期
关键词
D O I
10.7164/antibiotics.45.1626
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The effect was studied of the fungal cyclodepsipeptide antibiotics beauvericin and seven distinct enniatins on acyl-CoA: cholesterol acyltransferase (ACAT) activity. In an enzyme assay using rat liver microsomes. all the compounds were found to inhibit ACAT activity. The drug concentration that caused 50% inhibition (IC50 value) of the enzyme activity was determined to be 3.0 mum for beauvericin, indicating that the compound is one of the most potent ACAT inhibitors of microbial origin. Enniatins exhibited much higher IC50 values of 22 to 110 mum. More hydrophobic enniatins showed more potent inhibitory activity. Furthermore, the ACAT inhibitory activity was evaluated as inhibition of cholesteryl ester formation in a cell assay using J774 macrophages. Calculation of the ratio, CD50 value (the drug concentration causing 50% cell damage)/IC50 value of cholesteryl ester formation, indicated thal beauvericin shows the highest specificity. These data indicate that beauvericin is one of the most potent and specific ACAT inhibitors of microbial origin.
引用
收藏
页码:1626 / 1632
页数:7
相关论文
共 50 条
  • [21] EFFECTS OF ETHANOL ON THE ASSAY OF ACYL-COA - CHOLESTEROL ACYLTRANSFERASE (ACAT)
    SMITH, JL
    MADDEN, LJ
    DEJERSEY, J
    CLINICA CHIMICA ACTA, 1993, 215 (02) : 233 - 236
  • [22] Upregulation of acyl-CoA:cholesterol acyltransferase in chronic renal failure
    Liang, KH
    Vaziri, ND
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04): : E676 - E681
  • [23] Acyl-CoA: Cholesterol acyltransferase inhibitors from Magnolia obovata
    Kwon, BM
    Kim, MK
    Lee, SH
    Kim, JA
    Lee, IR
    Kim, YK
    Bok, SH
    PLANTA MEDICA, 1997, 63 (06) : 550 - 551
  • [25] Acyl-CoA binding protein (ACBP) regulates acyl-CoA:cholesterol acyltransferase (ACAT) in human mononuclear phagocytes
    Kerkhoff, C
    Beuck, M
    ThreigeRasmussen, J
    Spener, F
    Knudsen, J
    Schmitz, G
    BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1346 (02): : 163 - 172
  • [26] STRUCTURE-ACTIVITY-RELATIONSHIPS OF PYRIPYROPENES FUNGAL ACYL-COA - CHOLESTEROL ACYLTRANSFERASE INHIBITORS
    OBATA, R
    SUNAZUKA, T
    LI, ZR
    TOMODA, H
    OMURA, S
    JOURNAL OF ANTIBIOTICS, 1995, 48 (07): : 749 - 750
  • [27] Quantitation of the pool of cholesterol associated with acyl-CoA: Cholesterol acyltransferase in human fibroblasts
    Lange, Y
    Steck, TL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) : 13103 - 13108
  • [28] CONTROL OF HEPATIC ACYL-COA - CHOLESTEROL ACYLTRANSFERASE IN CHOLESTEROL-FED RATS
    HIGGINS, MJP
    PAPACHRISTODOULOU, DK
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1989, 17 (01) : 156 - 156
  • [29] Acyl-CoA: Cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice
    Kusunoki, J
    Hansoty, DK
    Aragane, K
    Fallon, JT
    Badimon, JJ
    Fisher, EA
    CIRCULATION, 2001, 103 (21) : 2604 - 2609
  • [30] Systemic Acyl-CoA: cholesterol acyltransferase inhibition reduces inflammation and improves vascular function in hypercholesterolemia
    Kharbanda, RK
    Wallace, S
    Walton, B
    Donald, A
    Cross, JM
    Deanfield, J
    CIRCULATION, 2005, 111 (06) : 804 - 807